Cost-effectiveness of tumor necrosis factor-α antagonist in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Dean Andrew Regier, Nick Bansback, Anne Dar Santos, Carlo A. Marra*

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The treatment of chronic arthritic diseases has undergone some dramatic changes over the past few years. In particular, a new class of drugs called the tumor necrosis factor-α antagonists has transformed the management of rheumatoid arthritis, and decision makers are now considering their use in psoriatic arthritis and ankylosing spondylitis. Whilst short-term clinical trials suggest that tumor necrosis factor-α antagonists improve physical function and pain linked to disease activity; this class of drug has generated controversy owing to its substantial cost. Pharmacoeconomic studies conclude that tumor necrosis factor-α antagonists result in significant increases in health-related quality of life; however, the cost-effectiveness of this class of drug remains uncertain, particularly in the treatment of psoriatic arthritis and ankylosing spondylitis. This paper reviews pharmacoeconomic analyses examining the cost-effectiveness of tumor necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Original languageEnglish
Pages (from-to)155-169
Number of pages15
JournalExpert Review of Pharmacoeconomics & Outcomes Research
Volume7
Issue number2
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Psoriatic Arthritis
Ankylosing Spondylitis
Cost-Benefit Analysis
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Pharmaceutical Economics
Pharmaceutical Preparations
Arthritis
Chronic Disease
Quality of Life
Clinical Trials
Costs and Cost Analysis
Pain
Therapeutics

Keywords

  • Adalimumab
  • Ankylosing spondylitis
  • Biological response modifier
  • Cost-effectiveness analysis
  • Etanercept
  • Infliximab
  • Psociatic arthritis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Cost-effectiveness of tumor necrosis factor-α antagonist in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. / Regier, Dean Andrew; Bansback, Nick; Dar Santos, Anne; Marra, Carlo A.

In: Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 7, No. 2, 04.2007, p. 155-169.

Research output: Contribution to journalArticle

@article{ccc231d725ff489a98844f0231933758,
title = "Cost-effectiveness of tumor necrosis factor-α antagonist in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis",
abstract = "The treatment of chronic arthritic diseases has undergone some dramatic changes over the past few years. In particular, a new class of drugs called the tumor necrosis factor-α antagonists has transformed the management of rheumatoid arthritis, and decision makers are now considering their use in psoriatic arthritis and ankylosing spondylitis. Whilst short-term clinical trials suggest that tumor necrosis factor-α antagonists improve physical function and pain linked to disease activity; this class of drug has generated controversy owing to its substantial cost. Pharmacoeconomic studies conclude that tumor necrosis factor-α antagonists result in significant increases in health-related quality of life; however, the cost-effectiveness of this class of drug remains uncertain, particularly in the treatment of psoriatic arthritis and ankylosing spondylitis. This paper reviews pharmacoeconomic analyses examining the cost-effectiveness of tumor necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.",
keywords = "Adalimumab, Ankylosing spondylitis, Biological response modifier, Cost-effectiveness analysis, Etanercept, Infliximab, Psociatic arthritis, Rheumatoid arthritis",
author = "Regier, {Dean Andrew} and Nick Bansback and {Dar Santos}, Anne and Marra, {Carlo A.}",
year = "2007",
month = "4",
doi = "10.1586/14737167.7.2.155",
language = "English",
volume = "7",
pages = "155--169",
journal = "Expert Review of Pharmacoeconomics & Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Cost-effectiveness of tumor necrosis factor-α antagonist in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

AU - Regier, Dean Andrew

AU - Bansback, Nick

AU - Dar Santos, Anne

AU - Marra, Carlo A.

PY - 2007/4

Y1 - 2007/4

N2 - The treatment of chronic arthritic diseases has undergone some dramatic changes over the past few years. In particular, a new class of drugs called the tumor necrosis factor-α antagonists has transformed the management of rheumatoid arthritis, and decision makers are now considering their use in psoriatic arthritis and ankylosing spondylitis. Whilst short-term clinical trials suggest that tumor necrosis factor-α antagonists improve physical function and pain linked to disease activity; this class of drug has generated controversy owing to its substantial cost. Pharmacoeconomic studies conclude that tumor necrosis factor-α antagonists result in significant increases in health-related quality of life; however, the cost-effectiveness of this class of drug remains uncertain, particularly in the treatment of psoriatic arthritis and ankylosing spondylitis. This paper reviews pharmacoeconomic analyses examining the cost-effectiveness of tumor necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

AB - The treatment of chronic arthritic diseases has undergone some dramatic changes over the past few years. In particular, a new class of drugs called the tumor necrosis factor-α antagonists has transformed the management of rheumatoid arthritis, and decision makers are now considering their use in psoriatic arthritis and ankylosing spondylitis. Whilst short-term clinical trials suggest that tumor necrosis factor-α antagonists improve physical function and pain linked to disease activity; this class of drug has generated controversy owing to its substantial cost. Pharmacoeconomic studies conclude that tumor necrosis factor-α antagonists result in significant increases in health-related quality of life; however, the cost-effectiveness of this class of drug remains uncertain, particularly in the treatment of psoriatic arthritis and ankylosing spondylitis. This paper reviews pharmacoeconomic analyses examining the cost-effectiveness of tumor necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

KW - Adalimumab

KW - Ankylosing spondylitis

KW - Biological response modifier

KW - Cost-effectiveness analysis

KW - Etanercept

KW - Infliximab

KW - Psociatic arthritis

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=34247572477&partnerID=8YFLogxK

U2 - 10.1586/14737167.7.2.155

DO - 10.1586/14737167.7.2.155

M3 - Article

VL - 7

SP - 155

EP - 169

JO - Expert Review of Pharmacoeconomics & Outcomes Research

JF - Expert Review of Pharmacoeconomics & Outcomes Research

SN - 1473-7167

IS - 2

ER -